S. Ohkubo

发表

A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity

Y. Sugimoto, N. Masuko, Y. Aoyagi, 2005, Cancer science.

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

F. Nakagawa, Y. Komiya, N. Fujita, 2019, Molecular Cancer Therapeutics.

Substrate Phage Display

S. Ohkubo, 2005 .

TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia

O. Ohara, Tomoaki Tanaka, K. Yamagata, 2021, Oncogene.

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

A. Fujioka, Kimihiro Ito, R. Wadhwa, 2019, Molecular Cancer Therapeutics.

Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.

T. Nishida, Tsuyoshi Takahashi, S. Ohkubo, 2019, European journal of cancer.

Identification of substrate sequences for membrane type-1 matrix metalloproteinase using bacteriophage peptide display library.

Y. Sugimoto, Y. Yamada, S. Ohkubo, 1999, Biochemical and biophysical research communications.

Substrate phage as a tool to identify novel substrate sequences of proteases.

Y. Sugimoto, Y. Yamada, S. Ohkubo, 2001, Combinatorial chemistry & high throughput screening.

Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

S. Sugano, Yutaka Suzuki, C. Prives, 2010, Proceedings of the National Academy of Sciences.

hCAS/CSE1L Associates with Chromatin and Regulates Expression of Select p53 Target Genes

C. Prives, Tomoaki Tanaka, I. Tatsuno, 2007, Cell.

Functionally distinct Gata3/Chd4 complexes coordinately establish T helper 2 (Th2) cell identity

S. Sugano, Yutaka Suzuki, Tomoaki Tanaka, 2013, Proceedings of the National Academy of Sciences.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

E. Calleja, A. Shimomura, U. Banerji, 2019, Molecular Cancer Therapeutics.

Excess HDM2 Impacts Cell Cycle and Apoptosis and Has a Selective Effect on p53-dependent Transcription*

C. Prives, Y. Taya, Tomoaki Tanaka, 2006, Journal of Biological Chemistry.

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

S. Ohkubo, M. Kitade, Y. Shibata, 2014, Molecular Cancer Therapeutics.

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells

A. Fujioka, T. Wakasa, S. Ohkubo, 2020, Cancer science.

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours

S. Hirota, F. Nakagawa, Y. Doki, 2019, British Journal of Cancer.

Genome editing of Nf1, Pten, and Trp53 in neonatal mice induces glioblastomas positive for oligodendrocyte lineage transcription factor 2

S. Ohkubo, Haruka Nagasaki, Takamasa Suzuki, 2021, Journal of toxicologic pathology.

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways

F. Nakagawa, S. Ohkubo, S. Tsuji, 2019, Cancer science.

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728

F. Nakagawa, Kimihiro Ito, J. Uchida, 2020, Cancer science.

Combination of pimitespib (TAS‐116) with sunitinib is an effective therapy for imatinib‐resistant gastrointestinal stromal tumors

H. Eguchi, Y. Doki, T. Nishida, 2023, International journal of cancer.

Pimitespib is effective on cecal GIST in a mouse model of familial GISTs with KIT-Asp820Tyr mutation through KIT signaling inhibition.

S. Hirota, T. Watabe, K. Kitajima, 2021, Experimental and molecular pathology.

Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.

K. T. Chong, Tatsuya Suzuki, S. Ohkubo, 2018, Journal of medicinal chemistry.

Pharmacologic dissection of the overlapping impact of heat shock protein family members on platelet function

L. Neckers, J. Trepel, J. Gestwicki, 2020, Journal of thrombosis and haemostasis : JTH.

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy

S. Ohkubo, T. Osada, Takamasa Suzuki, 2023, Scientific reports.

Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.

K. Tsumoto, S. Nagatoishi, S. Ohkubo, 2021, Journal of medicinal chemistry.

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90a and b, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in

S. Ohkubo, M. Kitade, Y. Shibata, 2014 .

Characterization of cell line with dedifferentiated GIST‐like features established from cecal GIST of familial GIST model mice

S. Hirota, S. Ohkubo, T. Kihara, 2023, Pathology international.

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

M. Ladanyi, R. Somwar, E. de Stanchina, 2023, Nature Cancer.